Opdigo says they are incorporating fusion proteins “such as aflibercept” that are “derisked.” I don’t know of another derisked fusion protein in the ophthalmology arena, so I’m puzzled by the “such as” phrasing.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”